ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease.

M Naomi Horiba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.